Credit Agricole S A raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 452,439 shares of the medical instruments supplier’s stock after buying an additional 12,892 shares during the period. Credit Agricole S A owned about 0.21% of Becton, Dickinson and worth $82,996,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. North Star Investment Management Corp. boosted its stake in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the last quarter. Crestwood Advisors Group LLC purchased a new stake in shares of Becton, Dickinson and during the first quarter worth about $101,000. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Financial Architects Inc boosted its stake in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the last quarter. Finally, QCI Asset Management Inc. NY boosted its stake in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.
Shares of Becton, Dickinson and Company (BDX) opened at 197.05 on Monday. The company has a 50-day moving average price of $197.67 and a 200 day moving average price of $186.53. The stock has a market capitalization of $42.03 billion, a P/E ratio of 32.73 and a beta of 1.05. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63.
Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period last year, the company posted $2.35 earnings per share. Analysts forecast that Becton, Dickinson and Company will post $9.45 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.
TRADEMARK VIOLATION WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://stocknewstimes.com/2017/08/07/becton-dickinson-and-company-nysebdx-position-increased-by-credit-agricole-s-a-updated-updated.html.
A number of equities analysts have issued reports on BDX shares. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Finally, Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $186.00 to $200.00 in a research note on Monday, April 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $194.69.
In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the transaction, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
